301080 百普赛斯
已收盘 07-11 15:00:00
资讯
新帖
简况
百普赛斯股价上涨2.67% 2024年度权益分派方案出炉
金融界 · 07-03
百普赛斯股价上涨2.67% 2024年度权益分派方案出炉
6月30日百普赛斯涨16.80%，中欧成长LOF基金重仓该股
证券之星 · 06-30
6月30日百普赛斯涨16.80%，中欧成长LOF基金重仓该股
百普赛斯：6月26日进行路演，招商基金、华夏基金等多家机构参与
证券之星 · 06-27
百普赛斯：6月26日进行路演，招商基金、华夏基金等多家机构参与
百普赛斯最新公告：调整回购股份价格上限至80.00元/股
证券之星 · 06-24
百普赛斯最新公告：调整回购股份价格上限至80.00元/股
6月24日百普赛斯涨8.58%，中欧成长LOF基金重仓该股
证券之星 · 06-24
6月24日百普赛斯涨8.58%，中欧成长LOF基金重仓该股
6月16日百普赛斯现1笔大宗交易 机构净买入2023.7万元
证券之星 · 06-16
6月16日百普赛斯现1笔大宗交易 机构净买入2023.7万元
百普赛斯涨8.79%，开源证券二周前给出“买入”评级
证券之星 · 06-12
百普赛斯涨8.79%，开源证券二周前给出“买入”评级
每周股票复盘：百普赛斯（301080）2025年股权激励计划获监事会认可
证券之星 · 06-07
每周股票复盘：百普赛斯（301080）2025年股权激励计划获监事会认可
百普赛斯股价微跌0.27% 开源证券给予买入评级
金融界 · 05-30
百普赛斯股价微跌0.27% 开源证券给予买入评级
开源证券给予百普赛斯买入评级：激励考核目标积极，常态化激励机制加强团队建设
每日经济新闻 · 05-29
开源证券给予百普赛斯买入评级：激励考核目标积极，常态化激励机制加强团队建设
百普赛斯(301080.SZ)拟推2025年限制性股票激励计划 授予价格为25.44元/股
智通财经 · 05-27
百普赛斯(301080.SZ)拟推2025年限制性股票激励计划 授予价格为25.44元/股
东方证券-百普赛斯-301080-2024年报&2025年一季报点评：业绩逐步改善，核心业务稳健增长-250521
市场资讯 · 05-21
东方证券-百普赛斯-301080-2024年报&2025年一季报点评：业绩逐步改善，核心业务稳健增长-250521
百普赛斯：未来将以资本市场为重要平台完善产业链布局
证券之星 · 05-15
百普赛斯：未来将以资本市场为重要平台完善产业链布局
百普赛斯：公司主要产品及服务应用于肿瘤、自身免疫疾病、心血管病、传染病等疾病的药物研发及生产环节
证券之星 · 05-15
百普赛斯：公司主要产品及服务应用于肿瘤、自身免疫疾病、心血管病、传染病等疾病的药物研发及生产环节
百普赛斯：公司不断推进技术的进步与创新，持续加强研发投入
证券之星 · 05-15
百普赛斯：公司不断推进技术的进步与创新，持续加强研发投入
百普赛斯：已推出即用型类器官等创新产品
金融界 · 05-15
百普赛斯：已推出即用型类器官等创新产品
百普赛斯：类器官是由多种类型的细胞组成的微型器官
证券之星 · 05-15
百普赛斯：类器官是由多种类型的细胞组成的微型器官
百普赛斯：2024年营业收入64,502.19万元同比增长18.65%
证券之星 · 05-15
百普赛斯：2024年营业收入64,502.19万元同比增长18.65%
【机构调研记录】泓德基金调研中密控股、百普赛斯
证券之星 · 05-12
【机构调研记录】泓德基金调研中密控股、百普赛斯
百普赛斯已回购25万股 金额1132万元
财中社 · 05-08
百普赛斯已回购25万股 金额1132万元
加载更多
公司概况
公司名称：
北京百普赛斯生物科技股份有限公司
所属行业：
研究和试验发展
上市日期：
2021-10-18
主营业务：
北京百普赛斯生物科技股份有限公司的主营业务是专业提供重组蛋白等关键生物试剂产品及技术服务。公司的主要产品是重组蛋白、检测服务、抗体、试剂盒及其他试剂。
发行价格：
112.50
{"stockData":{"symbol":"301080","market":"SZ","secType":"STK","nameCN":"百普赛斯","latestPrice":49.66,"timestamp":1752217383000,"preClose":48.62,"halted":0,"volume":3301030,"delay":0,"changeRate":0.0214,"floatShares":127000000,"shares":168000000,"eps":0.7968,"marketStatus":"已收盘","change":1.04,"latestTime":"07-11 15:00:00","open":48.2,"high":50.37,"low":48.18,"amount":163000000,"amplitude":0.045,"askPrice":49.67,"askSize":30,"bidPrice":49.66,"bidSize":3,"shortable":0,"etf":0,"ttmEps":0.7968,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1752456600000},"marketStatusCode":5,"adr":0,"adjPreClose":48.62,"symbolType":"stock","openAndCloseTimeList":[[1752197400000,1752204600000],[1752210000000,1752217200000]],"highLimit":53.48,"lowLimit":43.76,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":167848198,"isCdr":false,"pbRate":3.13,"roa":"--","peRate":62.324297,"roe":"1.54%","epsLYR":1.0319,"committee":-0.095652,"marketValue":8335000000,"turnoverRate":0.0261,"status":0,"floatMarketCap":6290000000},"requestUrl":"/m/hq/s/301080","defaultTab":"news","newsList":[{"id":"2548080290","title":"百普赛斯股价上涨2.67% 2024年度权益分派方案出炉","url":"https://stock-news.laohu8.com/highlight/detail?id=2548080290","media":"金融界","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548080290?lang=zh_cn&edition=full","pubTime":"2025-07-03 20:50","pubTimestamp":1751547046,"startTime":"0","endTime":"0","summary":"截至2025年7月3日15时6分，百普赛斯股价报72.78元，较前一交易日上涨1.89元，涨幅2.67%。当日开盘价为71.00元，最高触及74.24元，最低下探70.18元，成交额2.67亿元，换手率4.05%。百普赛斯是一家专注于生物医药领域的公司，主营业务涉及重组蛋白、抗体等生物试剂的研发与生产。根据公告，百普赛斯2024年度权益分派方案已获股东大会审议通过。股权登记日为2025年7月10日，除权除息日为7月11日。资金方面，7月3日主力资金净流入2253.42万元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/07/03205051468393.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["301080","BK0216"],"gpt_icon":0},{"id":"2547063746","title":"6月30日百普赛斯涨16.80%，中欧成长LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2547063746","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2547063746?lang=zh_cn&edition=full","pubTime":"2025-06-30 16:28","pubTimestamp":1751272126,"startTime":"0","endTime":"0","summary":"证券之星消息，6月30日百普赛斯涨16.80%创60日新高，收盘报71.53元，换手率7.84%，成交量7.1万手，成交额4.86亿元。重仓百普赛斯的前十大公募基金请见下表：该股最近90天内共有13家机构给出评级，买入评级13家；过去90天内机构目标均价为59.85。根据2025基金Q1季报公募基金重仓股数据，重仓该股的公募基金共16家，其中持有数量最多的公募基金为中欧基金的中欧成长LOF。中欧成长LOF目前规模为21.05亿元，最新净值1.7416，较上一交易日下跌0.03%，近一年上涨18.62%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025063000021091.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["166006","301080","BK0216"],"gpt_icon":0},{"id":"2546352742","title":"百普赛斯：6月26日进行路演，招商基金、华夏基金等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2546352742","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546352742?lang=zh_cn&edition=full","pubTime":"2025-06-27 22:32","pubTimestamp":1751034727,"startTime":"0","endTime":"0","summary":"证券之星消息，2025年6月27日百普赛斯发布公告称公司于2025年6月26日进行路演，招商基金、华夏基金、嘉实基金、中金基金、大家资产、兴业证券、信达证券、天风证券、其他26家机构参与。随着创新药行情暖，产业投入不断增加，重组蛋白、抗体等生物试剂产品及相关服务的需求也将持续增长，这将为公司带来更多的业务机会，推动公司业绩增长，进而对公司经营产生积极影响。上述活动不涉及应披露重大信息的情况。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025062700040026.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301080"],"gpt_icon":0},{"id":"2545207284","title":"百普赛斯最新公告：调整回购股份价格上限至80.00元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2545207284","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545207284?lang=zh_cn&edition=full","pubTime":"2025-06-24 20:01","pubTimestamp":1750766471,"startTime":"0","endTime":"0","summary":"百普赛斯(301080.SZ)公告称，为保障回购股份方案顺利实施，公司决定将回购股份价格上限由49.70元/股调整为80.00元/股。除上述调整外，回购方案的其他内容不变。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025062400034798.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301080"],"gpt_icon":0},{"id":"2545409976","title":"6月24日百普赛斯涨8.58%，中欧成长LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2545409976","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545409976?lang=zh_cn&edition=full","pubTime":"2025-06-24 16:33","pubTimestamp":1750754036,"startTime":"0","endTime":"0","summary":"证券之星消息，6月24日百普赛斯涨8.58%，收盘报57.48元，换手率3.55%，成交量3.22万手，成交额1.78亿元。重仓百普赛斯的前十大公募基金请见下表：该股最近90天内共有13家机构给出评级，买入评级13家；过去90天内机构目标均价为59.85。根据2025基金Q1季报公募基金重仓股数据，重仓该股的公募基金共16家，其中持有数量最多的公募基金为中欧基金的中欧成长LOF。中欧成长LOF目前规模为21.05亿元，最新净值1.6926，较上一交易日下跌0.54%，近一年上涨13.29%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025062400026403.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["166006","301080","BK0216"],"gpt_icon":0},{"id":"2543622508","title":"6月16日百普赛斯现1笔大宗交易 机构净买入2023.7万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2543622508","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543622508?lang=zh_cn&edition=full","pubTime":"2025-06-16 17:09","pubTimestamp":1750064963,"startTime":"0","endTime":"0","summary":"证券之星消息，6月16日百普赛斯发生大宗交易，交易数据如下：大宗交易成交价格57.82元，相对当日收盘价折价0.99%，成交35万股，成交金额2023.7万元，买方营业部为机构专用，卖方营业部为中国国际金融股份有限公司上海分公司。近三个月该股共发生1笔大宗交易，合计成交3500.0手，折价成交1笔。截至2025年6月16日收盘，百普赛斯报收于58.4元，下跌0.66%，换手率3.01%，成交量2.72万手，成交额1.59亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061600020971.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301080"],"gpt_icon":0},{"id":"2542772595","title":"百普赛斯涨8.79%，开源证券二周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2542772595","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542772595?lang=zh_cn&edition=full","pubTime":"2025-06-12 16:29","pubTimestamp":1749716955,"startTime":"0","endTime":"0","summary":"今日百普赛斯涨8.79%，收盘报59.8元。2025年5月29日，开源证券研究员余汝意,聂媛媛发布了对百普赛斯的研报《公司信息更新报告：激励考核目标积极，常态化激励机制加强团队建设》，该研报对百普赛斯给出“买入”评级。研报中预计2025-2026年为1.49/1.90亿元），EPS分别为1.41/1.85/2.27元，当前股价对应P/E分别为34.1/26.0/21.2倍，维持“买入”评级。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为招商证券的梁广楷。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061200023036.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301080","161027"],"gpt_icon":0},{"id":"2541891002","title":"每周股票复盘：百普赛斯（301080）2025年股权激励计划获监事会认可","url":"https://stock-news.laohu8.com/highlight/detail?id=2541891002","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2541891002?lang=zh_cn&edition=full","pubTime":"2025-06-07 08:29","pubTimestamp":1749256152,"startTime":"0","endTime":"0","summary":"截至2025年6月6日收盘，百普赛斯报收于53.7元，较上周的52.5元上涨2.29%。北京百普赛斯生物科技股份有限公司在2025年5月27日召开了第二届董事会第十七次会议和第二届监事会第十六次会议，审议并通过了关于2025年限制性股票激励计划和股票增值权激励计划的多项议案。2025年5月28日至6月6日，公司对激励对象的姓名和职务进行了内部公示，期间未收到任何异议。监事会认为，激励对象的主体资格合法、有效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025060700009333.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301080","BK0216"],"gpt_icon":0},{"id":"2539279612","title":"百普赛斯股价微跌0.27% 开源证券给予买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2539279612","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2539279612?lang=zh_cn&edition=full","pubTime":"2025-05-31 00:03","pubTimestamp":1748621038,"startTime":"0","endTime":"0","summary":"截至2025年5月30日收盘，百普赛斯股价报52.50元，较前一交易日下跌0.14元，跌幅0.27%。当日成交量为21159手，成交金额达1.12亿元。开源证券5月29日发布研报，给予百普赛斯买入评级。研报指出，公司发布的2025年股票及增值权激励计划有助于加强团队建设，考核目标积极彰显发展信心。同时，公司2025年一季度降本增效成果显著，利润端改善明显。全球新药研发需求不及预期、核心成员流失、新产品开发失败等风险因素需注意。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/05/31000350786696.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["301080","161027"],"gpt_icon":0},{"id":"2539137255","title":"开源证券给予百普赛斯买入评级：激励考核目标积极，常态化激励机制加强团队建设","url":"https://stock-news.laohu8.com/highlight/detail?id=2539137255","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2539137255?lang=zh_cn&edition=full","pubTime":"2025-05-29 17:24","pubTimestamp":1748510640,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 开源证券05月29日发布研报称，给予百普赛斯（301080.SZ，最新价：52.64元）买入评级。评级理由主要包括：1）公司发布2025年股票及增值权激励计划，常态化激励机制加强公司团队建设；2）激励计划考核目标积极，彰显公司对未来发展的坚定信心；3）公司2025Q1降本增效成果显著，利润端改善明显。风险提示：全球新药研发需求不及预期、核心成员流失、新产品开发失败等。（文章来源：每日经济新闻）\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-05-29/doc-ineyfqpv4855336.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-05-29/doc-ineyfqpv4855336.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["301080","161027"],"gpt_icon":0},{"id":"2538450415","title":"百普赛斯(301080.SZ)拟推2025年限制性股票激励计划 授予价格为25.44元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2538450415","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2538450415?lang=zh_cn&edition=full","pubTime":"2025-05-27 18:32","pubTimestamp":1748341963,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百普赛斯(301080.SZ)披露2025年限制性股票激励计划(草案)，该激励计划拟授予的限制性股票数量为146.0000万股，约占该激励计划草案公告时公司股本总额的1.22%。其中，首次授予120.2690万股，预留授予25.7310万股。该激励计划首次授予的激励对象不超过168人，限制性股票(含预留授予)的授予价格为25.44元/股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1298146.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"百普赛斯(301080.SZ)拟推2025年限制性股票激励计划 授予价格为25.44元/股","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301080","BK0216"],"gpt_icon":0},{"id":"2537953298","title":"东方证券-百普赛斯-301080-2024年报&2025年一季报点评：业绩逐步改善，核心业务稳健增长-250521","url":"https://stock-news.laohu8.com/highlight/detail?id=2537953298","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537953298?lang=zh_cn&edition=full","pubTime":"2025-05-21 23:09","pubTimestamp":1747840140,"startTime":"0","endTime":"0","summary":"公司发布年报，2024年实现营收6.5亿元；归母净利润1.2亿元；扣非归母净利润1.2亿元。 核心业务快速增长，境外收入延续高增长。2024年，公司实现境内收入2.2亿元，境外收入4.3亿元，扣除特定急性呼吸道传染病相关产品后的境外收入同比增长超过20%。2024年，公司投入研发费用1.7亿元。此外，2024年公司位于苏州的GMP级别生产厂房已正式投产，将为免疫细胞治疗药物的商业化生产提供坚实保障。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-05-21/doc-inexkerr5603330.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0012","BK0028","BK1147","BK1564","BK0216","BK0188","600958","BK0183","BK0276","301080","03958"],"gpt_icon":0},{"id":"2535833268","title":"百普赛斯：未来将以资本市场为重要平台完善产业链布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2535833268","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535833268?lang=zh_cn&edition=full","pubTime":"2025-05-15 08:57","pubTimestamp":1747270627,"startTime":"0","endTime":"0","summary":"证券之星消息，百普赛斯(301080)05月14日在投资者关系平台上答复投资者关心的问题。投资者提问：超募集资金全吃利息浪费辜负国家扶持本意，在考虑用来研发或并购重组价值链团队项目吗百普赛斯回复：尊敬的投资者您好！未来公司将以资本市场为重要平台，立足产业视角，围绕生命科学、医疗健康等领域设立投资平台。通过积极拓展和挖掘投资项目，完善产业链布局，提升公司的综合竞争力。感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025051500006018.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301080"],"gpt_icon":0},{"id":"2535331948","title":"百普赛斯：公司主要产品及服务应用于肿瘤、自身免疫疾病、心血管病、传染病等疾病的药物研发及生产环节","url":"https://stock-news.laohu8.com/highlight/detail?id=2535331948","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535331948?lang=zh_cn&edition=full","pubTime":"2025-05-15 08:51","pubTimestamp":1747270275,"startTime":"0","endTime":"0","summary":"证券之星消息，百普赛斯(301080)05月14日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的林董秘：贵司在蛋白抗体试剂方面维持国产龙头地位的状况下，请问下一步会布局医疗器械和实验仪器方面的业务吗？百普赛斯回复：尊敬的投资者您好！公司是一家专业提供重组蛋白、抗体等关键生物试剂及技术服务的高新技术企业，主要产品及服务应用于肿瘤、自身免疫疾病、心血管病、传染病等疾病的药物研发及生产环节。感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025051500005776.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301080"],"gpt_icon":0},{"id":"2535384368","title":"百普赛斯：公司不断推进技术的进步与创新，持续加强研发投入","url":"https://stock-news.laohu8.com/highlight/detail?id=2535384368","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535384368?lang=zh_cn&edition=full","pubTime":"2025-05-15 08:39","pubTimestamp":1747269558,"startTime":"0","endTime":"0","summary":"证券之星消息，百普赛斯05月14日在投资者关系平台上答复投资者关心的问题。投资者提问：相较于同行上市公司完整披露的专利动态信息，贵司年报中为何未包含2023年度专利申请及授权情况？公司已按照相关规定和要求保证信息披露真实、准确、完整。在研发方面，公司不断推进技术的进步与创新，持续加强研发投入，全面强化实验室和团队建设工作，通过新建实验室或外延并购的方式，积极拓展全球研发布局。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025051500005721.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301080","BK0216"],"gpt_icon":0},{"id":"2535818833","title":"百普赛斯：已推出即用型类器官等创新产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2535818833","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535818833?lang=zh_cn&edition=full","pubTime":"2025-05-15 08:37","pubTimestamp":1747269472,"startTime":"0","endTime":"0","summary":"金融界5月15日消息，有投资者在互动平台向百普赛斯提问：您好董秘！公司于2023年即推出了包括iPSC分化的即用型活体类器官在内的多种解决方案，是得益于与下游国际客户的紧密联系从而率先有所布局吗？公司回答表示：尊敬的投资者您好！类器官是由多种类型的细胞组成的微型器官，具有类似于真实器官的结构和功能特征，可用于研究和理解人体发育、疾病机制以及药物研发和安全性评估。在这一前沿领域，公司已推出即用型类器官、类器官分化试剂盒、类器官培养细胞因子等一系列创新产品，助力新型治疗方法的探索，加速药物研发进程。感谢您的关注。\n\n\r\n 责任编辑：栎树","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/05/15083750397552.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0216","301080"],"gpt_icon":0},{"id":"2535838152","title":"百普赛斯：类器官是由多种类型的细胞组成的微型器官","url":"https://stock-news.laohu8.com/highlight/detail?id=2535838152","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535838152?lang=zh_cn&edition=full","pubTime":"2025-05-15 08:36","pubTimestamp":1747269385,"startTime":"0","endTime":"0","summary":"证券之星消息，百普赛斯05月14日在投资者关系平台上答复投资者关心的问题。类器官是由多种类型的细胞组成的微型器官，具有类似于真实器官的结构和功能特征，可用于研究和理解人体发育、疾病机制以及药物研发和安全性评估。在这一前沿领域，公司已推出即用型类器官、类器官分化试剂盒、类器官培养细胞因子等一系列创新产品，助力新型治疗方法的探索，加速药物研发进程。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025051500005711.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301080","BK0216"],"gpt_icon":0},{"id":"2535838189","title":"百普赛斯：2024年营业收入64,502.19万元同比增长18.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2535838189","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535838189?lang=zh_cn&edition=full","pubTime":"2025-05-15 08:36","pubTimestamp":1747269382,"startTime":"0","endTime":"0","summary":"证券之星消息，百普赛斯05月14日在投资者关系平台上答复投资者关心的问题。2024 年，公司实现营业收入64,502.19万元，同比增长 18.65%，其中，境外收入同比增长超 20%，展现出良好的发展势头。进入 2025 年第一季度，公司业绩持续向好，实现营业收入 18,649.04 万元，同比增长27.73%，由于特定急性呼吸道传染病相关产品对公司整体收入增长仍有部分拖累，扣除该类产品收入后，公司增长表现更为亮眼。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025051500005706.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301080"],"gpt_icon":0},{"id":"2534256806","title":"【机构调研记录】泓德基金调研中密控股、百普赛斯","url":"https://stock-news.laohu8.com/highlight/detail?id=2534256806","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534256806?lang=zh_cn&edition=full","pubTime":"2025-05-12 08:02","pubTimestamp":1747008147,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及5月9日披露的机构调研信息，泓德基金近期对2家上市公司进行了调研，相关名单如下：1）中密控股 调研纪要：中密控股表示，一季度毛利率下滑主要由于增量业务占比增加，但增量业务毛利率再降可能性不大。2）百普赛斯 调研纪要：2024年，百普赛斯聚焦生物医药与细胞免疫治疗，实现营业收入64,502.19万元，同比增长18.65%，净利润12,383.25万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025051200001781.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0259","301080","BK0216","IE0005HP3H50.USD","300470"],"gpt_icon":0},{"id":"2533077959","title":"百普赛斯已回购25万股 金额1132万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2533077959","media":"财中社","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533077959?lang=zh_cn&edition=full","pubTime":"2025-05-08 17:45","pubTimestamp":1746697500,"startTime":"0","endTime":"0","summary":"5月8日，百普赛斯（301080）发布公告，截至2025年4月30日已回购25万股，占总股本的0.2109%，回购金额为1132万元，回购价格区间为41.82元/股至48.45元/股。2025年一季度，百普赛斯实现收入1.86亿元，归母净利润4058万元。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-05-08/doc-inevwchu5217506.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0216","301080"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1752328656142,"stockEarnings":[{"period":"1week","weight":-0.0202},{"period":"1month","weight":0.271},{"period":"3month","weight":0.6143},{"period":"6month","weight":0.5377},{"period":"1year","weight":1.011},{"period":"ytd","weight":0.5923}],"compareEarnings":[{"period":"1week","weight":0.0109},{"period":"1month","weight":0.0317},{"period":"3month","weight":0.084},{"period":"6month","weight":0.1078},{"period":"1year","weight":0.1817},{"period":"ytd","weight":0.0473}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京百普赛斯生物科技股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"10597人(较上一季度减少12.07%)","perCapita":"11953股","listingDate":"2021-10-18","address":"北京市大兴区北京经济技术开发区宏达北路8号4幢4层","registeredCapital":"16784万元","survey":" 北京百普赛斯生物科技股份有限公司的主营业务是专业提供重组蛋白等关键生物试剂产品及技术服务。公司的主要产品是重组蛋白、检测服务、抗体、试剂盒及其他试剂。","listedPrice":112.5},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百普赛斯(301080)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百普赛斯(301080)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百普赛斯,301080,百普赛斯股票,百普赛斯股票老虎,百普赛斯股票老虎国际,百普赛斯行情,百普赛斯股票行情,百普赛斯股价,百普赛斯股市,百普赛斯股票价格,百普赛斯股票交易,百普赛斯股票购买,百普赛斯股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百普赛斯(301080)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百普赛斯(301080)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}